base busi remain steadi jakafi revenu y-o-i
surpass consensu growth driven consist strong underli
patient demand myelofibrosi mf polycythemia vera pv
growth total patient product royalti jakavi olumi
respect full-year guidanc remain larg unchang updat
estim accordingli reiter buy view current stock valuat
undemand pipelin present upsid
plan file steroid-refractori agvhd
result pivot trial jakafi steroid-refractori acut graft-versus-
host diseas sr-agvhd demonstr overal respons rate orr
day commun fda threshold approv durabl respons rate
greater best orr number patient achiev respons
point studi best orr relev compar
previou proof-of-concept studi plan submit supplement new drug
applic nda fda result phase ruxolitinib vs
best support care sr-agvhd anticip readi launch
immedi upon approv see peak sale sr-agvhd
data random phase trial ruxolitinib cream adult patient atop
dermat present european academi dermatolog venerolog
congress septemb plan initi global pivot phase program
atop dermat potenti registr data pemigatinib inhibitor
cholangiocarcinoma bladder cancer anticip european societi
medic oncolog esmo plan submit nda cholangiocarcinoma
depend full data includ respons rate durat respons continu
dose arm ad bladder cancer trial respons rate expect
around in-lin competitor anticip mileston
initi phase trial baricitinib lupu success indic beyond
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani focus drug
develop hematology/oncolog
inflamm multipl market product
includ inhibitor jakafi approv
myelofibrosi polycythemia vera olumi
baricitinib approv ra eu us
iclusig cml emerg rich clinic
rate share buy see signific
valu market product jakafi ruxolitinib
mf pv see signific potenti
compani robust pipelin baricitinib
approv eu us ruxolitinib gvhd
fgfr inhibitor liquid solid
po deriv probability-adjust npv analysi includ
jakafi call jakavi ex-u mf pv jakafi/itacitnib gvhd
olumi iclusig earli pipelin also includ
approx net cash use wacc termin valu
downsid risk price object weaker-than-expect sale jakafi mf
pv unfavor efficaci and/or safeti data pipelin asset clinic trial
earlier-than-expect more-than-expect competit jakafi approv
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
